Interleukin-2 may improve survival outcomes in a subset of ALS patients Adding low-dose interleukin-2 to riluzole does not significantly reduce mortality in most patients with amyotrophic lateral sclerosis, but may have benefits for those with less aggressive disease.

#MedNews - Adding low-dose IL-2 to #riluzole does not significantly reduce mortality in most patients with #ALS, but may have benefits for those with less aggressive disease.

👉 buff.ly/KJp1M6q

#NeuroSky #MedSky

SARS-CoV-2 infection causes dopaminergic neuron senescence COVID-19 patients commonly present with signs of central nervous system and/or peripheral nervous system dysfunction. Here, we show that midbrain dopamine (DA) neurons derived from human pluripotent s...

#SARSCoV2 infection causes dopaminergic neuron senescence #LongCovid #riluzole #metformin #imatinib

pmc.ncbi.nlm.nih.gov/articles/PMC...